Epidemiology, antifungal susceptibility, risk factors and mortality of invasive candidiasis in neonates and children in a tertiary teaching hospital in Southwest China

Zeng, Zhangrui; Tian, Gang; Ding, Yinhuan; Yang, Kui; Deng, Jianzhi; Liu, Jinbo

doi:10.1111/myc.13146

Cited by 8 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With ongoing advances in chemotherapeutic regimens and supportive care measures, it is likely that the epidemiology of fungal infection in children with AML is evolving. Moreover, the recent shift towards non‐albicans Candida species, 13–15 along with the emergence of azole‐resistant Aspergillus spp 16 . and non‐aspergillus moulds 17–20 highlight the importance of accurate epidemiological data to inform prophylactic, diagnostic and treatment strategies.…”

Section: Introductionmentioning

confidence: 99%

Invasive fungal disease in children with acute myeloid leukaemia: An Australian multicentre 10‐year review

Yeoh

Moore

Kotecha

et al. 2021

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background Invasive fungal disease (IFD) is a common and important complication in children with acute myeloid leukaemia (AML). We describe the epidemiology of IFD in a large multicentre cohort of children with AML. Methods As part of the retrospective multicentre cohort TERIFIC (The Epidemiology and Risk factors for Invasive Fungal Infections in immunocompromised Children) study, proven/probable/possible IFD episodes occurring in children with primary or relapsed/refractory AML from 2003 to 2014 were analysed. Crude IFD prevalence, clinical characteristics, microbiology and treatment were assessed. Kaplan–Meier survival analysis was used to estimate 6‐month survival. Results There were 66 IFD episodes diagnosed in 63 children with AML. The majority (75.8%) of episodes occurred in the context of primary AML therapy. During primary AML therapy, the overall prevalence was 20.7% (95% CI 15.7%–26.5%) for proven/probable/possible IFD and 10.3% (95% CI 6.7%–15.0%) for proven/probable IFD. Of primary AML patients, 8.2% had IFD diagnosed during the first cycle of chemotherapy. Amongst pathogens implicated in proven/probable IFD episodes, 74.4% were moulds, over a third (37.9%) of which were non‐Aspergillus spp. Antifungal prophylaxis preceded 89.4% of IFD episodes, most commonly using fluconazole (50% of IFD episodes). All‐cause mortality at 6 months from IFD diagnosis was 16.7% with IFD‐related mortality of 7.6% (all in cases of proven IFD). Conclusions IFD is a common and serious complication during paediatric AML therapy. Mould infections, including non‐Aspergillus spp. predominated in this cohort. A systematic approach to the identification of patients at risk, and a targeted prevention strategy for IFD is needed.

show abstract

Section: Introductionmentioning

confidence: 99%

Invasive fungal disease in children with acute myeloid leukaemia: An Australian multicentre 10‐year review

Yeoh

Moore

Kotecha

et al. 2021

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…13 Overall mortality in paediatric patients is 10-14.4%, increasing up to 22% for neonates. 13,[38][39][40][41][42] The distribution of species is also different in neonates and children. Although C. albicans remains predominant in neonates, 38,40 non-albicans Candida species have become the predominant cause of invasive, paediatric candidiasis.…”

Section: Search Strategymentioning

confidence: 99%

“…Although C. albicans remains predominant in neonates, 38,40 non-albicans Candida species have become the predominant cause of invasive, paediatric candidiasis. [40][41][42][43][44] The proportion of C. albicans declines as the age of paediatric patients increases. 39,40 Question 2: What is the optimal collection and processing of blood and other cultures?…”

Section: Search Strategymentioning

confidence: 99%

Consensus guidelines for the diagnosis and management of invasive candidiasis in haematology, oncology and intensive care settings, 2021

Keighley

Cooley

Morris

et al. 2021

Internal Medicine Journal

View full text Add to dashboard Cite

Patients with haematological malignancies, haemopoietic stem cell transplant recipients and patients requiring admission to intensive care settings are at high risk for invasive candidiasis (IC). Over the past decade, there has been increased reporting of nonalbicans species and fluconazole resistance in Australia. These guidelines provide updated evidence-based recommendations for the diagnosis and management of IC in adult and paediatric haematology, oncology and intensive care settings. Optimal pharmacological and non-pharmacological management are discussed. Recent studies strengthen the recommendation for an echinocandin agent as first-line therapy for high-risk patients with IC. Mortality benefit has also been demonstrated for nonpharmacological management, including removal of central venous catheters, infectious diseases consultation and use of care bundles. Healthcare facilities managing immunocompromised patient populations should therefore adopt implementation strategies for these multimodal interventions.

show abstract

A metabolomics footprinting approach using GC-MS to study inhibitory effects of the fungal metabolite diplopyrone C against nosocomial pathogen biofilms

Salvatore,

Maione,

Imparato

et al. 2024

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

Epidemiology, antifungal susceptibility, risk factors and mortality of invasive candidiasis in neonates and children in a tertiary teaching hospital in Southwest China

Cited by 8 publications

References 35 publications

Invasive fungal disease in children with acute myeloid leukaemia: An Australian multicentre 10‐year review

Invasive fungal disease in children with acute myeloid leukaemia: An Australian multicentre 10‐year review

Consensus guidelines for the diagnosis and management of invasive candidiasis in haematology, oncology and intensive care settings, 2021

A metabolomics footprinting approach using GC-MS to study inhibitory effects of the fungal metabolite diplopyrone C against nosocomial pathogen biofilms

Contact Info

Product

Resources

About